Chardan Capital Thinks Immatics’ Stock is Going to Recover

By Carrie Williams

Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Immatics (IMTXResearch Report) today and set a price target of $28.00. The company’s shares closed last Tuesday at $10.00, close to its 52-week low of $9.51.

According to, Livshits is a 5-star analyst with an average return of 37.1% and a 69.7% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Rocket Pharmaceuticals, and Crispr Therapeutics AG.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Immatics with a $19.67 average price target.

See today’s analyst top recommended stocks >>

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Immatics NV is engaged in discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company’s pipeline consists of two lead product classes, engineered Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics (TCER). Each therapeutic modality has distinct attributes to produce the desired therapeutic effect for patients at different disease stages and with different types of tumors focusing on particularly hard-to-treat solid cancers.